Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Research analysts at Zacks Research dropped their Q3 2024 EPS estimates for shares of Axsome Therapeutics in a research report issued on Monday, October 21st. Zacks Research analyst R. Department now expects that the company will earn ($1.52) per share for the quarter, down from their previous forecast of ($1.42). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.73) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($1.31) EPS, FY2024 earnings at ($5.16) EPS, Q1 2025 earnings at ($1.52) EPS, Q2 2025 earnings at ($1.33) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($4.15) EPS, Q1 2026 earnings at ($0.59) EPS, Q2 2026 earnings at ($0.02) EPS and Q3 2026 earnings at $0.83 EPS.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its quarterly earnings results on Monday, August 5th. The company reported ($1.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.06. The business had revenue of $87.17 million for the quarter, compared to analysts’ expectations of $84.53 million. Axsome Therapeutics had a negative net margin of 105.85% and a negative return on equity of 117.46%.
Check Out Our Latest Stock Report on AXSM
Axsome Therapeutics Stock Performance
Shares of Axsome Therapeutics stock opened at $88.83 on Wednesday. The firm has a market capitalization of $4.22 billion, a P/E ratio of -13.92 and a beta of 1.26. The company has a quick ratio of 2.40, a current ratio of 2.48 and a debt-to-equity ratio of 1.77. The company has a 50 day moving average price of $90.02 and a 200 day moving average price of $81.94. Axsome Therapeutics has a 52 week low of $55.02 and a 52 week high of $98.40.
Institutional Investors Weigh In On Axsome Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its holdings in Axsome Therapeutics by 1.0% in the 4th quarter. Wellington Management Group LLP now owns 239,819 shares of the company’s stock valued at $19,087,000 after buying an additional 2,265 shares during the period. Janiczek Wealth Management LLC purchased a new position in shares of Axsome Therapeutics during the first quarter worth approximately $97,000. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Axsome Therapeutics by 14.6% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 69,483 shares of the company’s stock worth $5,545,000 after purchasing an additional 8,867 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Axsome Therapeutics by 2.9% during the first quarter. Principal Financial Group Inc. now owns 9,773 shares of the company’s stock worth $780,000 after purchasing an additional 276 shares during the period. Finally, Privium Fund Management B.V. lifted its holdings in shares of Axsome Therapeutics by 13.9% during the first quarter. Privium Fund Management B.V. now owns 82,032 shares of the company’s stock worth $6,546,000 after purchasing an additional 10,000 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.
Insider Activity
In related news, Director Mark E. Saad sold 11,016 shares of Axsome Therapeutics stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total value of $1,005,870.96. Following the sale, the director now owns 10,002 shares of the company’s stock, valued at approximately $913,282.62. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Mark E. Saad sold 11,016 shares of Axsome Therapeutics stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total value of $1,005,870.96. Following the sale, the director now owns 10,002 shares of the company’s stock, valued at approximately $913,282.62. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Mark L. Jacobson sold 47,739 shares of Axsome Therapeutics stock in a transaction on Friday, August 9th. The shares were sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the completion of the sale, the chief operating officer now directly owns 5,783 shares in the company, valued at $487,275.58. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 22.40% of the company’s stock.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Read More
- Five stocks we like better than Axsome Therapeutics
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Dividend Capture Strategy: What You Need to Know
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What is the FTSE 100 index?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.